News

Video

Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

Author(s):

Ulka Vaishampayan, MD,Alan Tan, MD
Related Videos
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.
Stephanie Graff, MD, and Chandler Park, FACP
Elias Jabbour, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Shubham Pant, MD, MBBS
Related Content
Michael Wang, MD
December 18th 2024

Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma

Jaffer A. Ajani, MD, GI medical oncologist, professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
November 14th 2024

FDA Approval Insights: Zolbetuximab for CLDN18.2+ HER2-Negative Gastric and GEJ Adenocarcinoma

ASH Meeting | Image credit: © Nittaya – stock.adobe.com
December 9th 2024

Isatuximab/VRd Elicits Sustained MRD Rates in Newly Diagnosed Myeloma

Oncology Unplugged
November 6th 2024

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

NDI-101159 in Heavily Pretreated RCC
December 3rd 2024

NDI-101150 Demonstrates Antitumor Activity, Safety in Heavily Pretreated RCC

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024